U.S. markets closed
  • S&P Futures

    3,295.00
    +7.75 (+0.24%)
     
  • Dow Futures

    27,123.00
    +80.00 (+0.30%)
     
  • Nasdaq Futures

    11,153.00
    +16.50 (+0.15%)
     
  • Russell 2000 Futures

    1,474.80
    +7.60 (+0.52%)
     
  • Crude Oil

    40.04
    -0.21 (-0.52%)
     
  • Gold

    1,864.30
    -2.00 (-0.11%)
     
  • Silver

    23.06
    -0.04 (-0.16%)
     
  • EUR/USD

    1.1633
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • Vix

    26.38
    -2.13 (-7.47%)
     
  • GBP/USD

    1.2763
    +0.0018 (+0.14%)
     
  • USD/JPY

    105.4100
    -0.1360 (-0.13%)
     
  • BTC-USD

    10,907.93
    +129.12 (+1.20%)
     
  • CMC Crypto 200

    233.48
    +15.65 (+7.19%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,335.27
    +130.65 (+0.56%)
     

Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020

HOUSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 15, 2020 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2020 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 7973458. A live audio webcast of the call will also be available on the Events section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event. 

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.

For more information, please visit the Company's website at http://www.biopathholdings.com.  

Contact Information:
                                   
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com 

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369